Ryuichi Harada
Nobuyuki Okamura
Shozo Furumoto3
Kazuhiko Yanai- 1Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
- 2Division of Pharmacology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
- 3Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Neurodegenerative diseases characterized by pathological protein accumulation in cells are termed “proteinopathies.” Although various protein aggregates share cross-β-sheet structures, actual conformations vary among each type of protein deposit. Recent progress in the development of radiotracers for positron emission tomography (PET) has enabled the visualization of protein aggregates in living brains. Amyloid PET tracers have been developed, and are widely used for the diagnosis of Alzheimer’s disease and non-invasive assessment of amyloid burden in clinical trials of anti-dementia drugs. Furthermore, several tau PET tracers have been successfully developed and used in the clinical studies. However, recent studies have identified the presence of off-target binding of radiotracers in areas of tau deposition, suggesting that concomitant neuroinflammatory changes might affect tracer binding. In contrast to amyloid and tau PET, there are no established tracers for imaging Lewy bodies in the human brain. In this review, we describe lessons learned from the development of PET tracers and discuss the future direction of tracer development for protein misfolding diseases.
Introduction
Proteinopathies are neurodegenerative diseases characterized by pathological accumulation of amyloid-β (Aβ), tau, α-synuclein, and TDP-43 in the cells. Tauopathies, characterized by tau protein accumulation, include Alzheimer’s disease (AD), some variants of frontotemporal lobar degeneration (FTLD), frontotemporal dementia with parkinsonism linked to chromosome-17 (FTLD-17), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), argyrophilic grain disease (AGD), and chronic traumatic encephalopathy (CTE). AD is a mixed proteinopathy characterized by abnormal accumulation of extracellular Aβ and intracellular tau protein. α-Synucleinopathies, characterized by pathological accumulation of α-synuclein, include Parkinson’s disease (PD), Lewy bodies disease (LBD), and multiple system atrophy (MSA). TDP-43 proteinopathies include some variants of FTLD and amyotrophic lateral sclerosis (ALS). Genetic, pathological, and biochemical evidence strongly suggests that protein accumulation causes neurodegenerative disease, although the precise etiology and mechanisms underlying these processes remain unknown. Historically, these neuropathological lesions could only be identified by histopathological examination at autopsy. Neuropathologists described the distributions of these lesions in many patients and proposed a classification of their regional distribution (Thal et al., 2002; Braak et al., 2006a; Hyman et al., 2012). Braak staging, which is based on cross-sectional autopsy studies, represents the most commonly used classification system for Aβ, tau, α-synuclein, and TDP-43, (Braak and Braak, 1991; Braak et al., 2003; Brettschneider et al., 2013). Importantly, the amount and spatial distribution of protein depositions is highly correlated with the severity of disease (Bierer et al., 1995; Braak et al., 2006b). Non-invasive detection of abnormal protein deposits would therefore be useful for accurate diagnosis, disease monitoring, and evaluation of the efficacy of anti-dementia treatments.
Positron emission tomography (PET) using specific radiotracers provides regional and pathophysiological information in a non-invasive manner in living human subjects. Although PET imaging is more expensive than examining body fluid biomarkers, such as blood and cerebrospinal fluid (CSF), it is advantageous because it enables the spatial assessment of brain lesions as well as accurate, reliable, and reproducible quantitative measurements. Following the successful imaging of amyloid with Pittsburgh compound B (PiB; Klunk et al., 2004), fluorinated alternatives have been developed in clinical studies and approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA; Mathis et al., 2017). These tracers are thioflavin and stilbene derivatives, which bind the cross-β-sheet structures of aggregated proteins. Many β-sheet binding compounds have been reported through the development of amyloid PET tracers (Furumoto et al., 2007). Several putative tau PET tracers have also been developed and evaluated in humans. In a clinical trial, these tracers demonstrated elevated retention in brain regions susceptible to tau deposition (Villemagne et al., 2015). However, tau pathology is more complicated than Aβ pathology, owing to its heterogeneous histopathology possibly resulting from isoform composition and ultrastructural conformation (for in depth review see Villemagne et al., 2012; Harada et al., 2016c). Furthermore, first generation tau tracers such as 11C-PBB3, 18F-AV1451 (also known as flortaucipir; T807), and 18F-THK5351 result in off-target binding (Okamura and Yanai, 2017). Recently, 18F-THK5351 was reported to bind with high affinity to monoamine oxidase-B (MAO-B), contributing to a high level of in vivo PET signal (Harada et al., 2017; Ng et al., 2017). In this review, we describe our experiences and lessons learned from the development of tau PET tracers, and discuss the future of radiotracer development for other proteinopathies.
Characteristics of Protein Aggregates
Amyloid-β, tau, and α-synuclein are highly insoluble when accumulated in the diseased brain. They comprise amyloid, a filamentous protein which has a cross-β-sheet structure in which individual β-strands run perpendicular to the fiber axis (Serpell et al., 2000; Figure 1). In most cases, these protein aggregates can be stained with histological dyes, such as Congo red and thioflavin-S, which bind the cross-β-sheet structures. Tau aggregates are hyperphosphorylated, and form twisted filaments called paired helical filaments (PHFs), which have a diameter of 8–20 nm and a stereotypical periodicity of 80 nm as observed by electron microscopy (EM). X-ray diffraction of amyloid plaques and PHFs from AD brains reveals unique characteristics, including a sharp reflection at 4.76-Å spacing and a diffuse reflection at about 10.6-Å spacing (Kirschner et al., 1986). However, there are various isoforms of tau in the human brain, leading to diverse ultrastructures, spatial distributions, and clinical phenotypes in tauopathies. Tau deposits in neurodegenerative diseases contain different isoform compositions: 3 repeat (3R) and 4 repeat (4R) tau in AD, predominantly 4R tau in CBD and PSP, and 3R tau in Pick’s disease. This leads to different affected cell types (e.g., neurons, astrocytes, oligodendrocytes) and histopathologies (e.g., neurofibrillary tangles and neuropil threads in AD, astrocytic plaques in CBD, tufted astrocytes in PSP, and Pick’s bodies in Pick’s disease). Ultrastructural and biochemical analyses reveal that the detailed composition and structure of tau deposits differ between CBD and PSP, despite both of these diseases being 4R tauopathies (Arai et al., 2004; Taniguchi-Watanabe et al., 2016). Because protein aggregates are highly insoluble, it is difficult to resolve the detailed structure of native aggregates in human brain tissue using conventional techniques such as X-ray crystallography and nuclear magnetic resonance (NMR). Thus, it is difficult to design rationally selective PET tracers. However, a recent study using a novel single particle cryo-EM approach revealed the detailed structure of native tau filaments from an AD brain (Fitzpatrick et al., 2017). The structure of the β-helix or the protofilament interface of PHF-tau may prove to be binding sites for selective tau PET ligands, owing to their specificities. Although the binding sites of tau PET ligands are complicated (Cai et al., 2016), this breakthrough may help in understanding ligand-protein interactions, and accelerate the development of new rationally designed PET tracers. Indeed, a Nobel Prize in chemistry was awarded for cryo-EM in 2017 (Bertozzi, 2017), supporting the potential of this technique to further the development of new tracers.
FIGURE 1. Illustration of cross-β structure in protein aggregates and proposed binding mechanism of β-sheet ligands such as thioflavin-T.
Properties Required for Pet Tracers
Protein aggregates consisting of Aβ, tau, and α-synuclein predominantly form cross-β sheet structures, laminated assemblies of secondary structure β-sheets. Thus, β-sheet ligands such as thioflavin-T could be useful in the development of PET tracers for imaging protein aggregates. One of the most well-described β-sheet ligands is thioflavin-T, which is considered to bind with long axis of amyloid fibrils, having cross β-sheet structures in which individual β-strands run perpendicular to the fiber axis (Figure 1; Krebs et al., 2005). As described previously (Villemagne et al., 2012; Okamura et al., 2014b), useful neuroimaging radiotracers must possess the following chemical and pharmacological properties (summarized in Table 1): brain–blood barrier (BBB) permeability, ability to undergo rapid clearance from normal brain tissue and blood, and ability to bind with high affinity and specificity to targets.
TABLE 1. Properties required for PET tracers.
Positron emission tomography radiotracers are often radiolabeled with 11C or 18F. In general, 11C-labeled tracers are easier to design, as 11C can be introduced into a methyl group. However, 11C-labeled tracers must be radiolabeled in each PET center, owing to the short half-life of 11C (t1/2 = 20 min). On the other hand, 18F has a longer half-life (t1/2 = 110 min), allowing for easier commercial application.
Binding affinity of a ligand for its target is a critical factor in in vivo imaging. Binding sites (Bmax) and binding affinity (dissociation constant; Kd,) can be predicted using in vitro saturation binding assays in homogenized tissue. At steady state, (Bmax/Kd) is used to calculate the binding potential (BP), and can be estimated using PET data. The rate constants for dissociation (koff; min−1) and association (kon; nM−1min−1) can also be predicted as an index of binding affinity and kinetics. The dissociation constant (Kd) is calculated as the ratio (koff/kon). High-affinity ligands are characterized by low koff and high kon, yielding a low Kd. These parameters serve as a good index of the binding properties of PET radiotracers. The most successful neuroimaging radiotracers for imaging amyloid possess a high binding affinity with Kd values of less than 10 nM (Mathis et al., 2003; Choi et al., 2009; Ni et al., 2013). However, reports of these parameters in the literature should be carefully interpreted as they largely depend on assay conditions. Dissociation constants (Kd) can also be assessed using in vitro autoradiography of human brain sections (Zhang et al., 2012; Maruyama et al., 2013; Xia et al., 2013). Binding inhibition constant (Ki) is alternatively estimated if test compounds are structurally related to one radioligand and could be a good indicator of binding affinity for the efficient screening of a number of non-radiolabeled candidate compounds (Furumoto et al., 2007). Recombinant proteins are widely used in binding assays for screening protein-ligand interactions (Mathis et al., 2003; Fodero-Tavoletti et al., 2007; Thompson et al., 2009). However, assays using native protein aggregates derived from human brain tissue represent a more reliable method for measuring the binding affinities of ligands.
Several misfolded proteins share cross β-sheet structures and are present in the neocortex in neurodegenerative diseases (e.g., Aβ and tau in AD, α-synuclein in LBD). In case of AD, there are far fewer tau aggregates than Aβ aggregates in the cortex (5–20 times fewer; Villemagne et al., 2012). Therefore, tau PET tracers require 20–50 times higher selectivity than Aβ, as estimated by simulation studies (Schafer et al., 2012). Further, the density of binding sites in α-synuclein and TDP-43 aggregates is much lower than that in tau and Aβ aggregates. In vitro autoradiography of human brain tissue is a reliable method to assess the binding selectivity of radioligands if the assays are performed at low nanomolar ligand concentrations, such as those achieved in brain tissue during a PET scan. In vitro autoradiography can also identify non-specific binding of radiotracers. However, a change in the assay conditions, such as washing and fixation procedures, can affect in vitro autoradiography results. For example, ethanol is commonly used in the differentiation process to mask non-specific and off-target binding. However, this treatment is not representative of physiological conditions and may damage the native structures of proteins. Fixation of brain tissue also affects autoradiography results. Pathologists generally use formalin-fixed paraffin embedded tissue for diagnostic procedures; however, the process of fixation may affect the native conformation of target and non-target proteins.
In order to allow for BBB penetration via passive diffusion, PET tracers should be small molecules (<450 Da). Useful PET radiotracers show initial brain uptake of more than 5% of an intravenously injected dose. Initial brain uptake depends not only on BBB penetration, but also blood flow, plasma radiotracer concentration, and free fraction of the radiotracer in the plasma and brain. Lipophilicity is a critical property that determines brain uptake. Ideally, a radiotracer should be moderately lipophilic, with an octanol-water partition coefficient (logP value) in the range of 0.9–2.5. Rapid clearance from normal tissues without non-specific binding is also desirable, as slower pharmacokinetics prolong the time it takes to reach steady state in a PET scan. In preclinical studies, the ratio of brain uptake 2–30 min after intravenous injection of tracers is a useful index of the clearance of tracers from normal tissues. Furthermore, radiotracers for neuroimaging should be stable and metabolized peripherally. Radiolabeled metabolites should be polar, and exhibit no brain entry or interaction with target proteins. In 18F-labeled tracers, defluorination can cause the accumulation of 18F in the bone, which could interfere with the visual assessment and quantification of radiotracer binding.
Screening of β-Sheet Ligands
As previously mentioned, small organic compounds that possess a high affinity for β-sheet structures are potential candidates for PET tracers in the imaging of proteinopathies. Planar compounds potentially bind to the cross β-sheet structure of protein aggregates. Congo red, thioflavin-S, and thioflavin-T are histological dyes that have traditionally been used for the visualization of amyloid lesions. Therefore, much effort has been made to optimize derivatives of these in the development of amyloid PET tracers. The first successful radiotracer for Aβ is 11C-PiB, a thioflavin-T derivative (Mathis et al., 2012). 18F-labeled amyloid PET tracers such as Florbetapir (AmyvidTM), Flutemetamol (VizamylTM), and Florbetaben (NeuroCeqTM) have also been developed and approved by the FDA and EMA. Identifying lead compounds for imaging proteinopathies other than Aβ has proven challenging, as most β-sheet binding ligands have a high affinity for Aβ fibrils. Although protein aggregates share a predominantly cross-β-sheet structure, they have distinct conformations. In fact, several fluorescent compounds display different emission spectra when bound to Aβ plaques and tau pathology in AD brain sections, suggesting that these compounds would interact with Aβ and tau aggregates differently (Harada et al., 2014). Fluorescence staining is useful for evaluating binding ability for initial screening processes. However, this method is very low throughput, and requires postmortem human brain samples. Previously, synthetic fibrils generated from recombinant proteins such as tau protein were used for the binding evaluation, but they cannot be expected to fully recapitulate the binding to native pathology. In fact, we have experienced the discrepancy of the binding data between synthetic fibrils and tissues containing native conformation of protein aggregates (Zhang et al., 2012; Okamura et al., 2013). Therefore, researchers have attempted to develop efficient and reliable high-throughput screening assays to identify lead compounds for imaging proteinopathies such as tau, α-synuclein, and TDP-43 aggregates. For example, tissue-based high throughput screening utilized with mass spectrometry imaging have been proposed (Yoshimi et al., 2015), but this field seems to be a big challenge.
Development of Tau Pet Tracers
Compared with the development of amyloid PET tracers, there was no lead compound available in the development of selective PET tracer for tau or α-synuclein. In the case of tau, Okamura et al. (2005) identified quinoline and styryl-benzimidazole derivatives that clearly stained neurofibrillary tangles, neuropil threads, and dystrophic neurites in AD brain sections. After successful identification of these derivatives, a quinoline derivative 11C-BF158 was synthesized and evaluated in human brain sections. In vitro autoradiography of 11C-BF158 revealed preferential binding in tau-rich regions over Aβ-rich regions (Okamura et al., 2005). In addition, 11C-BF158 showed high BBB permeability in mice, suggesting that quinoline derivatives could be good candidates for tau PET tracers (Figure 2). Additionally, we synthesized the 18F-quinoline derivative 18F-THK523. Small animal PET studies have demonstrated higher tracer retention in rTg4510 tau transgenic mice compared to littermate controls (Fodero-Tavoletti et al., 2011). Direct comparison of 18F-THK523 with 11C-PiB, 18F-BF227, and 18F-FDDNP in AD brain sections revealed different binding distributions of 18F-THK523, which co-localized with tau immunostaining and Gallyas Braak silver staining (Harada et al., 2013). A first-in-human study of 18F-THK523 demonstrated significant tracer retention in the temporal parietal, orbitofrontal lobe, and hippocampus of AD patients, and different tracer retention compared to 11C-PiB in the same subjects (Villemagne et al., 2014). However, 18F-THK523 retention was significantly lower in gray matter than in white matter, suggesting insufficient binding affinity of this tracer to PHF-tau in the AD brain.
FIGURE 2. Chemical structures and flowchart of the development of tau PET tracers.
We further optimized the quinoline derivatives (Tago et al., 2014; Furumoto et al., 2017) and developed 18F-THK5105 and 18F-THK5117, which possess higher affinity for tau fibrils and better pharmacokinetics than 18F-THK523 (Okamura et al., 2013; Lemoine et al., 2015). These tracers were evaluated in human studies (Okamura et al., 2014a; Harada et al., 2015). In these clinical studies, radiotracer retention was elevated in the inferior temporal lobe of patients with AD where tau pathology was frequently observed at autopsy. 18F-THK5105 retention in the neocortex was significantly correlated with disease severity of AD patients (Okamura et al., 2014a). The spatial pattern of 18F-THK5117 retention in AD was consistent with that of 18F-THK5105, and different from that of 11C-PiB. However, both 18F-THK5105 and 18F-THK5117 were retained in white matter. As observed in amyloid PET tracers, β-sheet ligands may bind to white matter in a non-specific manner, owing to the presence of β-sheet-rich myelin basic protein (Stankoff et al., 2011). Lipophilicity of compounds can strongly influence white matter binding. For example, increasing hydrophilicity via the introduction of nitrogen to a benzene ring can reduce non-specific binding of the tracer to white matter, as observed using 11C-AZD2184, a pyridine derivative of 11C-PiB (Johnson et al., 2009; Nyberg et al., 2009).
To reduce non-specific tracer retention in white matter, we additionally developed 18F-THK5351, a pyridine derivative of 18F-THK5117 (Harada et al., 2016b; Tago et al., 2016b). Indeed, 18F-THK5351 is more hydrophilic than 18F-THK5117 (Log P = 1.5 vs 2.3). As expected, 18F-THK5351 showed less white matter binding and improved pharmacokinetics. A fluoropropanol side chain of THK5117 contains a chiral center. 18F-THK5117 is a racemic compound with equal amounts of S- and R-enantiomers. In general, each enantiomer exhibits different biological properties including binding affinity, pharmacokinetics, and metabolism. In our analysis, S-enantiomers of THK compounds were superior to R-enantiomers with respect to pharmacokinetics, tolerance to defluorination, and binding affinity to human brain homogenates (Tago et al., 2016a,b). In 18F-THK5351 PET study, we observed prominent tracer retention in the inferior temporal cortex of AD patients. 18F-THK5351 successfully reduced non-specific retention in white matter and exhibited superior pharmacokinetics than 18F-THK5117 (Harada et al., 2016b; Betthauser et al., 2017). The major radiolabeled metabolite of this tracer was a sulfate conjugate, which appears to be generated outside of (and does not enter into) the brain (Harada et al., 2016a).
In clinical studies of AD patients, regional tracer retention correlates well with glucose hypometabolism. and mirrors the clinical and neuroanatomical variability in AD variants (Chiotis et al., 2016; Saint-Aubert et al., 2016; Kang et al., 2017) as observed in 18F-AV1451 PET studies (Ossenkoppele et al., 2016). Furthermore, prominent tracer retention is observed in sites susceptible to tau deposition in non-AD tauopathies such as CBD and PSP (Chiotis et al., 2016; Kikuchi et al., 2016; Ishiki et al., 2017). However, 18F-THK5351 also accumulates in the temporal cortex in semantic variant primary progressive aphasia (svPPA), although notably, more than 90% of svPPA cases are FTLD-TDP type C pathology (Spinelli et al., 2017).
Since tau PET ligands recognize cross-β sheet structure of PHF-tau, they could detect extracellular ghost tangles as well as intracellular neurofibrillary tangles. However, they are not sensitive to non-argyrophilic pretangles that contain AT8-immunoreactive soluble tau (Braak et al., 1994; Sun et al., 2002). Tau immunohistochemistry and Gallyas Braak silver staining detect neurofibrillary pathology in layers II, III, and V of the neocortex in AD patients (Braak et al., 2006a). Interestingly, 3H-THK5351 binds preferentially to neurofibrillary tangles in the pyramidal cell layer (V) compared to the granule cell layers (II/III), although the granule cell layers also contain neurofibrillary tangles. Similar binding characteristics were observed for 18F-AV1451 (Lowe et al., 2016). These observations suggest variation in the structural conformation and maturity of neurofibrillary tangles in AD brains. As described by Lowe et al. (2016), this has very important implications on the sensitivity of tau PET imaging at different stages; tau PET ligands may detect more mature tangles than anticipated.
18F-THK5351 satisfies the requirements for neuroimaging PET tracers. However, 18F-THK5351 exhibits off-target binding in the basal ganglia and thalamus. Recent blocking studies have identified MAO-B as an off-target binding substrate of 18F-THK5351. In a human study, a single oral dose (10 mg) of selegiline, an MAO-B inhibitor, reduced 18F-THK5351 signal in the basal ganglia as well as neocortex (Ng et al., 2017). In addition, an autopsy imaging study of 18F-THK5351 in an AD patient demonstrated significant correlation of in vivo 18F-THK5351 signals with MAO-B levels (Harada et al., 2017). This indicates that 18F-THK5351 is not a selective PET tracer for tau. In our previous studies, THK5351-MAO-B binding was overlooked in human brain sections because the formaldehyde-fixed sections had been used in autoradiography analyses (Okamura et al., 2013; Harada et al., 2015, 2016b). Fixation of tissues with formalin, paraformaldehyde, or alcohol denatures native protein structures and deactivates native enzyme activity, while protein deposits such as neurofibrillary tangles and amyloid plaques are relatively stable. In fact, 3H-THK5351 binding in the putamen disappears after fixation with 4% paraformaldehyde, while laminar THK5351 binding in the neocortex remains detectable even after fixation. Therefore, selectivity of radiotracers should be assessed in unfixed frozen tissue. A receptor panel screen (i.e., ligand binding assay) has also been utilized to identify off-target binding of tracer candidates. However, functional assays are commonly used to assess a compound’s binding ability to a particular enzyme, and the panel screen was originally designed for the development of therapeutic drugs. In our experience, functional assays are less sensitive in the evaluation of the binding ability of a compound to an enzyme compared to ligand-binding assays.
18F-AV1451 (also known as flortaucipir, T807) was developed as tau PET tracer (Figure 2). This tracer showed high binding affinity and specificity to tau deposits in AD brain sections. 18F-AV1451 has been clinically evaluated in many PET centers (Villemagne et al., 2015) revealing a robust difference between AD patients and normal elderly controls. The spatial distribution of 18F-AV1451 followed the known distribution of tau aggregates in the neocortex, glucose hypometabolism in FDG-PET, and cortical atrophy in MRI (Schwarz et al., 2016; Hanseeuw et al., 2017; Xia et al., 2017). 18F-AV1451 PET studies have also demonstrated a distinct pattern of tracer binding in non-AD tauopathies such as PSP, CBD, and microtubule associated tau (MAPT) mutation carriers (Smith et al., 2016, 2017b; Cho et al., 2017a; Passamonti et al., 2017; Schonhaut et al., 2017; Spina et al., 2017). However, 18F-AV1451 retention was also observed in non-tauopathies such as svPPA and MSA (Cho et al., 2017b; Makaretz et al., 2017). This is similar to the findings in studies of 18F-THK5351 PET. Off-target binding of 18F-AV1451 is observed in the basal ganglia, choroid plexus, and midbrain. Previous studies suggested that 18F-AV1451 binds with high affinity to MAO-A and neuromelanin (Marquie et al., 2015; Vermeiren et al., 2015), although this fails to account for off-target retention of this tracer in the basal ganglia. A recent study demonstrated a lack of correlation between in vivo 18F-AV1451 retention and tau pathology in cases with non-AD tauopathy (Josephs et al., 2016; Marquie et al., 2017; Smith et al., 2017a). While 18F-AV1451 retention was elevated in the basal ganglia of PSP cases, in vitro assays failed to detect significant 18F-AV1451 binding to 4R tau deposits in the basal ganglia of postmortem brains. It is speculated that these discrepancies are caused by the fixation of brain samples or the use of ethanol during differentiation, which can mask off-target and non-specific binding of radiotracer. Indeed, a recent autoradiography study successfully detected displaceable binding of 18F-AV1451 in the basal ganglia without using ethanol (Walji et al., 2016). In vitro binding assays demonstrated that a MAO-A inhibitor blocked 18F-AV1451 binding in the basal ganglia. However, the effect was relatively modest compared to that of self-blocking, indicating the presence of other off-target substrates of AV1451. 18F-AV1451 PET in PD patients revealed no significant differences in tracer uptake between patients who received MAO-B inhibitors (selegiline and rasagiline) and those who did not (Hansen et al., 2017), indicating that MAO-B is not an off-target substrate of 18F-AV1451 in the basal ganglia. Another frequent site of 18F-AV1451 binding is the choroid plexus which is closely located to the hippocampus. Although tau protein deposits in epithelial cells may contribute to 18F-AV1451 binding, it is still unclear why this tracer accumulates in the choroid plexus.
11C-PBB3 was developed to visualize a broad range of tauopathies in the human brain. In clinical PET studies, significant 11C-PBB3 retention has been detected in the hippocampus and neocortex of AD patients. 11C-PBB3 retention was also observed in the striatum and midbrain of PSP patients, suggesting high binding affinity of this tracer to 4R tau deposits. Off-target binding of 11C-PBB3 has been observed in the basal ganglia, the longitudinal sinus and the choroid plexus. The 18F-labeled derivatives of PBB3 (18F-AM-PBB3 and 18F-PM-PBB3) have been newly developed and showed less off-target signals in the basal ganglia and higher specific signals than 11C-PBB3. Recently, new-generation tau PET tracers have been developed to overcome the drawbacks of the first-generation tracers (Villemagne, 2017). 18F-MK6240, 18F-RO69558948, and 18F-PI2620 (Figure 2) also showed excellent pharmacokinetics and high binding affinity selectivity for tau aggregates in AD brain tissue (Hostetler et al., 2016; Honer et al., 2018). Preclinical binding analysis also has suggested lower binding affinity of these second-generation tracers to MAO-A and MAO-B, than the binding affinity of the first-generation tracers such as 18F-AV1451 and 18F-THK5351. A recent first-in-human study showed no detectable signal in the basal ganglia and brainstem, suggesting high binding selectivity of these tracers to tau deposition in patients with AD (Villemagne, 2017; Lohith et al., 2018; Wong et al., 2018). Further validation studies are required to confirm the binding selectivity of these tracers.
Challenges for Imaging Other Proteinopathies
It is challenging to develop novel PET tracers for imaging other misfolded proteins such as α-synuclein and TDP-43, due to the density of binding sites of α-synuclein and TDP-43 aggregates in diseased brains is lower than that of Aβ and tau in AD brains. Like tau pathology, α-synuclein shows distinct cellular localization in synucleinopathies. Lewy bodies are observed in neurons in PD and dementia with Lewy bodies (DLB), while glial cytoplasmic inclusions (GCIs) are observed in oligodendrocytes of MSA (Shah et al., 2014). BF227 was originally developed for imaging Aβ in the brain (Kudo et al., 2007). However, this compound shows high binding affinity for recombinant α-synuclein fibrils. A 11C-BF227 PET study demonstrated a significant increase in tracer retention in brain regions susceptible to α-synuclein deposition in MSA (Kikuchi et al., 2010). Recently, 11C-PBB3 was also reported to have binding affinity to GCIs in a subset of MSA cases (Koga et al., 2017). 11C-PBB3 PET demonstrated significant tracer retention in MSA patients compared to age-matched control subjects (Perez-Soriano et al., 2017). Currently, no PET tracer is available for imaging Lewy bodies in the human brain. High binding affinity and selectivity for Lewy bodies are required to image Lewy pathology in vivo, because α-synuclein pathology is frequently concomitant with AD pathology.
Several groups have reported novel scaffold ligands that demonstrate affinity for α-synuclein aggregates. A phenothiazine derivative, 125I-SIL23, showed binding affinity for in vitro generated α-synuclein as well as PD brain homogenates (Bagchi et al., 2013). 11C- and 18F-analogs of phenothiazine derivatives appear to demonstrate insufficient binding affinity for α-synuclein in PD brain tissues. 18F-46a, which is a series of 3-(benzylidene)indolin-2-one, showed better selectivity for in vitro generated α-synuclein fibrils compared to Aβ and tau (Chu et al., 2015).
TDP-43 is frequently observed in some variants of FTLD and ALS as a primary histopathological feature. TDP-43 pathology is also concomitant with AD, PD-related disorders, Huntington’s disease, and rare disorders such as Guam ALS, as a secondary histopathological feature (Chen-Plotkin et al., 2010). TDP-43 pathology is more complicated than other proteinopathies, because there are many histopathologic subtypes, including FTLD-TDP types 1-4 and ALS-TDP (Mackenzie et al., 2010). One concern in the development of TDP-43 tracers is the density of cross β-sheet structures in TDP-43 aggregates. Although partial peptides from TDP-43 can form amyloid structures (Shimonaka et al., 2016), most TDP-43 aggregates may not have cross β-sheet structures (Cairns et al., 2007). One study reported that thioflavin-S-positive skein-like inclusions are present in only 28% of ALS cases (Robinson et al., 2013), while another study found that thioflavin-S-positive TDP-43 inclusions were present in most FTLD-TDP and ALS cases (Bigio et al., 2013). Further validation studies are required to better understand the structure of TDP-43 aggregates. If the majority of TDP-43 aggregates do not contain cross β-sheet structures, other approaches will be required (i.e., non-β-sheet ligands). Bigio et al. (2013) also observed a high density of thioflavin-S-positive astrocytosis in the superficial frontal cortex of FTLD-TDP type A. Although the significance of thioflavin-S-positive astrocytosis remains unknown, proteins containing cross β-sheet conformation might be critical in understanding the histopathology of FTLD-TDP type A.
Conclusion
Here, we describe our experiences and lessons learned from the development of tau PET tracers, and discuss issues surrounding the development of new tracers for other proteinopathies. Advances in structural biology will aid in the development of novel PET tracers for imaging proteinopathies.
Author Contributions
RH and NO wrote the manuscript. SF and KY revised the manuscript.
Funding
This study was supported by research funds from GE Healthcare, Grant-in-Aid for Scientific Research (B) (15H04900), and Grant-in-Aid for Scientific Research on Innovative Areas (Brain Protein Aging and Dementia Control) (26117003) from MEXT.
Conflict of Interest Statement
NO owns stock of CLINO Co. Ltd. NO and SF are scientific consultants for the CLINO Co. Ltd. RH and KY have no conflict of interest.
References
Arai, T., Ikeda, K., Akiyama, H., Nonaka, T., Hasegawa, M., Ishiguro, K., et al. (2004). Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann. Neurol. 55, 72–79. doi: 10.1002/ana.10793
Bagchi, D. P., Yu, L., Perlmutter, J. S., Xu, J., Mach, R. H., Tu, Z., et al. (2013). Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One 8:e55031. doi: 10.1371/journal.pone.0055031
Bertozzi, C. (2017). Atoms out of blobs: CryoEM takes the Nobel prize in chemistry. ACS Cent. Sci. 3:1056. doi: 10.1021/acscentsci.7b00494
Betthauser, T. J., Lao, P. J., Murali, D., Barnhart, T. E., Furumoto, S., Okamura, N., et al. (2017). In vivo comparison of tau radioligands 18F-THK-5351 and 18F-THK-5317. J. Nucl. Med. 58, 996–1002. doi: 10.2967/jnumed.116.182980
Bierer, L. M., Hof, P. R., Purohit, D. P., Carlin, L., Schmeidler, J., Davis, K. L., et al. (1995). Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s disease. Arch. Neurol. 52, 81–88. doi: 10.1001/archneur.1995.00540250089017
Bigio, E. H., Wu, J. Y., Deng, H. X., Bit-Ivan, E. N., Mao, Q., Ganti, R., et al. (2013). Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol. 125, 463–465. doi: 10.1007/s00401-013-1089-6
Braak, E., Braak, H., and Mandelkow, E. M. (1994). A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 87, 554–567. doi: 10.1007/BF00293315
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., and Del Tredici, K. (2006a). Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389–404.
Braak, H., Rub, U., and Del Tredici, K. (2006b). Cognitive decline correlates with neuropathological stage in Parkinson’s disease. J. Neurol. Sci. 248, 255–258.
Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259. doi: 10.1007/BF00308809
Braak, H., Del Tredici, K., Rub, U., De Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211. doi: 10.1016/S0197-4580(02)00065-9
Brettschneider, J., Del Tredici, K., Toledo, J. B., Robinson, J. L., Irwin, D. J., Grossman, M., et al. (2013). Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 74, 20–38. doi: 10.1002/ana.23937
Cai, L., Qu, B., Hurtle, B. T., Dadiboyena, S., Diaz-Arrastia, R., and Pike, V. W. (2016). Candidate PET radioligand development for neurofibrillary tangles: two distinct radioligand binding sites identified in postmortem Alzheimer’s disease brain. ACS Chem. Neurosci. 7, 897–911. doi: 10.1021/acschemneuro.6b00051
Cairns, N. J., Neumann, M., Bigio, E. H., Holm, I. E., Troost, D., Hatanpaa, K. J., et al. (2007). TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 171, 227–240. doi: 10.2353/ajpath.2007.070182
Chen-Plotkin, A. S., Lee, V. M., and Trojanowski, J. Q. (2010). TAR DNA-binding protein 43 in neurodegenerative disease. Nat. Rev. Neurol. 6, 211–220. doi: 10.1038/nrneurol.2010.18
Chiotis, K., Saint-Aubert, L., Savitcheva, I., Jelic, V., Andersen, P., Jonasson, M., et al. (2016). Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm. Eur. J. Nucl. Med. Mol. Imaging 43, 1686–1699. doi: 10.1007/s00259-016-3363-z
Cho, H., Baek, M. S., Choi, J. Y., Lee, S. H., Kim, J. S., Ryu, Y. H., et al. (2017a). 18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome. Neurology 89, 1170–1178. doi: 10.1212/WNL.0000000000004364
Cho, H., Choi, J. Y., Lee, S. H., Ryu, Y. H., Lee, M. S., and Lyoo, C. H. (2017b). 18 F-AV-1451 binds to putamen in multiple system atrophy. Mov. Disord. 32, 171–173. doi: 10.1212/WNL.0000000000004364
Choi, S. R., Golding, G., Zhuang, Z., Zhang, W., Lim, N., Hefti, F., et al. (2009). Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 50, 1887–1894. doi: 10.2967/jnumed.109.065284
Chu, W., Zhou, D., Gaba, V., Liu, J., Li, S., Peng, X., et al. (2015). Design, synthesis, and characterization of 3-(Benzylidene)indolin-2-one derivatives as ligands for alpha-synuclein fibrils. J. Med. Chem. 58, 6002–6017. doi: 10.1021/acs.jmedchem.5b00571
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., et al. (2017). Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature 547, 185–190. doi: 10.1038/nature23002
Fodero-Tavoletti, M. T., Okamura, N., Furumoto, S., Mulligan, R. S., Connor, A. R., Mclean, C. A., et al. (2011). 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 134, 1089–1100. doi: 10.1093/brain/awr038
Fodero-Tavoletti, M. T., Smith, D. P., Mclean, C. A., Adlard, P. A., Barnham, K. J., Foster, L. E., et al. (2007). In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J. Neurosci. 27, 10365–10371. doi: 10.1523/JNEUROSCI.0630-07.2007
Furumoto, S., Okamura, N., Iwata, R., Yanai, K., Arai, H., and Kudo, Y. (2007). Recent advances in the development of amyloid imaging agents. Curr. Top. Med. Chem. 7, 1773–1789. doi: 10.2174/156802607782507402
Furumoto, S., Tago, T., Harada, R., Kudo, Y., and Okamura, N. (2017). 18F-Labeled 2-Arylquinoline derivatives for tau imaging: chemical, radiochemical, biological and clinical features. Curr. Alzheimer Res. 14, 178–185. doi: 10.2174/1567205013666160620121811
Hanseeuw, B. J., Betensky, R. A., Schultz, A. P., Papp, K. V., Mormino, E. C., Sepulcre, J., et al. (2017). Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann. Neurol. 81, 583–596. doi: 10.1002/ana.24910
Hansen, A. K., Brooks, D. J., and Borghammer, P. (2017). MAO-B inhibitors do not block in vivo flortaucipir([18F]-AV-1451) binding. Mol. Imaging Biol. 20, 356–360. doi: 10.1007/s11307-017-1143-1
Harada, R., Furumoto, S., Tago, T., Furukawa, K., Ishiki, A., Tomita, N., et al. (2016a). Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351. Eur. J. Nucl. Med. Mol. Imaging 43, 2211–2218. doi: 10.1007/s00259-016-3453-y
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., et al. (2016b). 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J. Nucl. Med. 57, 208–214. doi: 10.2967/jnumed.115.164848
Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., et al. (2016c). Characteristics of tau and its ligands in PET imaging. Biomolecules 6:7. doi: 10.3390/biom6010007
Harada, R., Ishiki, A., Kai, H., Sato, N., Furukawa, K., Furumoto, S., et al. (2017). Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer’s disease. J. Nucl. Med. 59, 671–674. doi: 10.2967/jnumed.117.197426
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., et al. (2015). [(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 42, 1052–1061. doi: 10.1007/s00259-015-3035-4
Harada, R., Okamura, N., Furumoto, S., Tago, T., Maruyama, M., Higuchi, M., et al. (2013). Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology. Eur. J. Nucl. Med. Mol. Imaging 40, 125–132. doi: 10.1007/s00259-012-2261-2
Harada, R., Okamura, N., Furumoto, S., Yoshikawa, T., Arai, H., Yanai, K., et al. (2014). Use of a benzimidazole derivative BF-188 in fluorescence multispectral imaging for selective visualization of tau protein fibrils in the Alzheimer’s disease brain. Mol. Imaging Biol. 16, 19–27. doi: 10.1007/s11307-013-0667-2
Honer, M., Gobbi, L., Knust, H., Kuwabara, H., Muri, D., Koerner, M., et al. (2018). Preclinical evaluation of (18)F-RO 6958948, (11)C-RO 6931643, and (11)C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease. J. Nucl. Med. 59, 675–681. doi: 10.2967/jnumed.117.196741
Hostetler, E. D., Walji, A. M., Zeng, Z., Miller, P., Bennacef, I., Salinas, C., et al. (2016). Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J. Nucl. Med. 57, 1599–1606. doi: 10.2967/jnumed.115.171678
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., et al. (2012). National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 8, 1–13. doi: 10.1016/j.jalz.2011.10.007
Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., et al. (2017). Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy. Eur. J. Neurol. 24, 130–136. doi: 10.1111/ene.13164
Johnson, A. E., Jeppsson, F., Sandell, J., Wensbo, D., Neelissen, J. A., Jureus, A., et al. (2009). AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. J. Neurochem. 108, 1177–1186. doi: 10.1111/j.1471-4159.2008.05861.x
Josephs, K. A., Whitwell, J. L., Tacik, P., Duffy, J. R., Senjem, M. L., Tosakulwong, N., et al. (2016). [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 132, 931–933. doi: 10.1007/s00401-016-1618-1
Kang, J. M., Lee, S. Y., Seo, S., Jeong, H. J., Woo, S. H., Lee, H., et al. (2017). Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer’s disease. Neurobiol. Aging 59, 210–219. doi: 10.1016/j.neurobiolaging.2017.08.008
Kikuchi, A., Okamura, N., Hasegawa, T., Harada, R., Watanuki, S., Funaki, Y., et al. (2016). In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 87, 2309–2316. doi: 10.1212/WNL.0000000000003375
Kikuchi, A., Takeda, A., Okamura, N., Tashiro, M., Hasegawa, T., Furumoto, S., et al. (2010). In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 133, 1772–1778. doi: 10.1093/brain/awq091
Kirschner, D. A., Abraham, C., and Selkoe, D. J. (1986). X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc. Natl. Acad. Sci. U.S.A. 83, 503–507. doi: 10.1073/pnas.83.2.503
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306–319. doi: 10.1002/ana.20009
Koga, S., Ono, M., Sahara, N., Higuchi, M., and Dickson, D. W. (2017). Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to alpha-synuclein pathology. Mov. Disord. 32, 884–892. doi: 10.1002/mds.27013
Krebs, M. R., Bromley, E. H., and Donald, A. M. (2005). The binding of thioflavin-T to amyloid fibrils: localisation and implications. J. Struct. Biol. 149, 30–37. doi: 10.1016/j.jsb.2004.08.002
Kudo, Y., Okamura, N., Furumoto, S., Tashiro, M., Furukawa, K., Maruyama, M., et al. (2007). 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer’s disease patients. J. Nucl. Med. 48, 553–561. doi: 10.2967/jnumed.106.037556
Lemoine, L., Saint-Aubert, L., Marutle, A., Antoni, G., Eriksson, J. P., Ghetti, B., et al. (2015). Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol. Commun. 3:40. doi: 10.1186/s40478-015-0220-4
Lohith, T. G., Bennacef, I., Vandenberghe, R., Vandenbulcke, M., Salinas-Valenzuela, C., Declercq, R., et al. (2018). First-in-human brain imaging of Alzheimer dementia patients and elderly controls with (18)F-MK-6240, a PET tracer targeting neurofibrillary tangle pathology. J. Nucl. Med. doi: 10.2967/jnumed.118.208215 [Epub ahead of print].
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., et al. (2016). An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol. Commun. 4:58. doi: 10.1186/s40478-016-0315-6
Mackenzie, I. R., Rademakers, R., and Neumann, M. (2010). TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9, 995–1007. doi: 10.1016/S1474-4422(10)70195-2
Makaretz, S. J., Quimby, M., Collins, J., Makris, N., Mcginnis, S., Schultz, A., et al. (2017). Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp-2017-316409 [Epub ahead of print].
Marquie, M., Normandin, M. D., Meltzer, A. C., Siao Tick Chong, M., Andrea, N. V., Anton-Fernandez, A., et al. (2017). Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann. Neurol. 81, 117–128. doi: 10.1002/ana.24844
Marquie, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., et al. (2015). Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 78, 787–800. doi: 10.1002/ana.24517
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., et al. (2013). Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094–1108. doi: 10.1016/j.neuron.2013.07.037
Mathis, C. A., Lopresti, B. J., Ikonomovic, M. D., and Klunk, W. E. (2017). Small-molecule PET tracers for imaging proteinopathies. Semin. Nucl. Med. 47, 553–575. doi: 10.1053/j.semnuclmed.2017.06.003
Mathis, C. A., Mason, N. S., Lopresti, B. J., and Klunk, W. E. (2012). Development of positron emission tomography beta-amyloid plaque imaging agents. Semin. Nucl. Med. 42, 423–432. doi: 10.1053/j.semnuclmed.2012.07.001
Mathis, C. A., Wang, Y., Holt, D. P., Huang, G. F., Debnath, M. L., and Klunk, W. E. (2003). Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 46, 2740–2754. doi: 10.1021/jm030026b
Ng, K. P., Pascoal, T. A., Mathotaarachchi, S., Therriault, J., Kang, M. S., Shin, M., et al. (2017). Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res. Ther. 9:25. doi: 10.1186/s13195-017-0253-y
Ni, R., Gillberg, P. G., Bergfors, A., Marutle, A., and Nordberg, A. (2013). Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain 136, 2217–2227. doi: 10.1093/brain/awt142
Nyberg, S., Jonhagen, M. E., Cselenyi, Z., Halldin, C., Julin, P., Olsson, H., et al. (2009). Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184. Eur. J. Nucl. Med. Mol. Imaging 36,1859–1863. doi: 10.1007/s00259-009-1182-1
Okamura, N., Furumoto, S., Fodero-Tavoletti, M. T., Mulligan, R. S., Harada, R., Yates, P., et al. (2014a). Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137, 1762–1771. doi: 10.1093/brain/awu064
Okamura, N., Harada, R., Furumoto, S., Arai, H., Yanai, K., and Kudo, Y. (2014b). Tau PET imaging in Alzheimer’s disease. Curr. Neurol. Neurosci. Rep. 14:500. doi: 10.1007/s11910-014-0500-6
Okamura, N., Furumoto, S., Harada, R., Tago, T., Yoshikawa, T., Fodero-Tavoletti, M., et al. (2013). Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J. Nucl. Med. 54, 1420–1427. doi: 10.2967/jnumed.112.117341
Okamura, N., Suemoto, T., Furumoto, S., Suzuki, M., Shimadzu, H., Akatsu, H., et al. (2005). Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer’s disease. J. Neurosci. 25,10857–10862. doi: 10.1523/JNEUROSCI.1738-05.2005
Okamura, N., and Yanai, K. (2017). Brain imaging: applications of tau PET imaging. Nat. Rev. Neurol. 13, 197–198. doi: 10.1038/nrneurol.2017.38
Ossenkoppele, R., Schonhaut, D. R., Scholl, M., Lockhart, S. N., Ayakta, N., Baker, S. L., et al. (2016). Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 139, 1551–1567. doi: 10.1093/brain/aww027
Passamonti, L., Vazquez Rodriguez, P., Hong, Y. T., Allinson, K. S., Williamson, D., Borchert, R. J., et al. (2017). 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain 140, 781–791. doi: 10.1093/brain/aww340
Perez-Soriano, A., Arena, J. E., Dinelle, K., Miao, Q., Mckenzie, J., Neilson, N., et al. (2017). PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins. Mov. Disord. 32, 1016–1024. doi: 10.1002/mds.27029
Robinson, J. L., Geser, F., Stieber, A., Umoh, M., Kwong, L. K., Van Deerlin, V. M., et al. (2013). TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol. 125, 121–131. doi: 10.1007/s00401-012-1055-8
Saint-Aubert, L., Almkvist, O., Chiotis, K., Almeida, R., Wall, A., and Nordberg, A. (2016). Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease. Alzheimers Res. Ther. 8:38. doi: 10.1186/s13195-016-0204-z
Schafer, K. N., Kim, S., Matzavinos, A., and Kuret, J. (2012). Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer’s disease: a simulation study. Neuroimage 60, 1724–1733. doi: 10.1016/j.neuroimage.2012.01.066
Schonhaut, D. R., Mcmillan, C. T., Spina, S., Dickerson, B. C., Siderowf, A., Devous, M. D., et al. (2017). 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann. Neurol. 82, 622–634. doi: 10.1002/ana.25060
Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., et al. (2016). Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139,1539–1550. doi: 10.1093/brain/aww023
Serpell, L. C., Berriman, J., Jakes, R., Goedert, M., and Crowther, R. A. (2000). Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. U.S.A. 97, 4897–4902. doi: 10.1073/pnas.97.9.4897
Shah, M., Seibyl, J., Cartier, A., Bhatt, R., and Catafau, A. M. (2014). Molecular imaging insights into neurodegeneration: focus on alpha-synuclein radiotracers. J. Nucl. Med. 55, 1397–1400. doi: 10.2967/jnumed.113.136515
Shimonaka, S., Nonaka, T., Suzuki, G., Hisanaga, S., and Hasegawa, M. (2016). Templated aggregation of TAR DNA-binding protein of 43 kDa (TDP-43) by seeding with TDP-43 peptide fibrils. J. Biol. Chem. 291, 8896–8907. doi: 10.1074/jbc.M115.713552
Smith, R., Puschmann, A., Scholl, M., Ohlsson, T., Van Swieten, J., Honer, M., et al. (2016). 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 139, 2372–2379. doi: 10.1093/brain/aww163
Smith, R., Scholl, M., Honer, M., Nilsson, C. F., Englund, E., and Hansson, O. (2017a). Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathol. 133, 149–151. doi: 10.1007/s00401-016-1650-1
Smith, R., Scholl, M., Widner, H., Van Westen, D., Svenningsson, P., Hagerstrom, D., et al. (2017b). In vivo retention of 18F-AV-1451 in corticobasal syndrome. Neurology 89, 845–853. doi: 10.1212/WNL.0000000000004264
Spina, S., Schonhaut, D. R., Boeve, B. F., Seeley, W. W., Ossenkoppele, R., O’neil, J. P., et al. (2017). Frontotemporal dementia with the V337M MAPT mutation: tau-PET and pathology correlations. Neurology 88, 758–766. doi: 10.1212/WNL.0000000000003636
Spinelli, E. G., Mandelli, M. L., Miller, Z. A., Santos-Santos, M. A., Wilson, S. M., Agosta, F., et al. (2017). Typical and atypical pathology in primary progressive aphasia variants. Ann. Neurol. 81, 430–443. doi: 10.1002/ana.24885
Stankoff, B., Freeman, L., Aigrot, M. S., Chardain, A., Dolle, F., Williams, A., et al. (2011). Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-(1)(1)C]-2-(4′-methylaminophenyl)- 6-hydroxybenzothiazole. Ann. Neurol. 69, 673–680. doi: 10.1002/ana.22320
Sun, A., Nguyen, X. V., and Bing, G. (2002). Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J. Histochem. Cytochem. 50, 463–472. doi: 10.1177/002215540205000403
Tago, T., Furumoto, S., Okamura, N., Harada, R., Adachi, H., Ishikawa, Y., et al. (2016a). Preclinical evaluation of [(18)F]THK-5105 enantiomers: effects of chirality on its effectiveness as a tau imaging radiotracer. Mol. Imaging Biol. 18, 258–266. doi: 10.1007/s11307-015-0879-8
Tago, T., Furumoto, S., Okamura, N., Harada, R., Adachi, H., Ishikawa, Y., et al. (2016b). Structure-activity relationship of 2-Arylquinolines as PET imaging tracers for tau pathology in Alzheimer disease. J. Nucl. Med. 57, 608–614. doi: 10.2967/jnumed.115.166652
Tago, T., Furumoto, S., Okamura, N., Harada, R., Ishikawa, Y., Arai, H., et al. (2014). Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. J. Labelled Comp. Radiopharm. 57, 18–24. doi: 10.1002/jlcr.3133
Taniguchi-Watanabe, S., Arai, T., Kametani, F., Nonaka, T., Masuda-Suzukake, M., Tarutani, A., et al. (2016). Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 131, 267–280. doi: 10.1007/s00401-015-1503-3
Thal, D. R., Rub, U., Orantes, M., and Braak, H. (2002). Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791–1800. doi: 10.1212/WNL.58.12.1791
Thompson, P. W., Ye, L., Morgenstern, J. L., Sue, L., Beach, T. G., Judd, D. J., et al. (2009). Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies. J. Neurochem. 109, 623–630. doi: 10.1111/j.1471-4159.2009.05996.x
Vermeiren, C., Mercier, J., Viot, D., Mairet-Coello, G., Hannestad, J., Courade, J.-P., et al. (2015). T 807, a reported selective tau tracer, binds with nanomolar affinity to monoamine oxidase A. Alzheimers Dement. 11(Suppl. 7), 283. doi: 10.1016/j.jalz.2015.07.381
Villemagne, V. L. (2017). Selective tau imaging: Der Stand der Dinge. J. Nucl. Med. 59, 175–176. doi: 10.2967/jnumed.117.198325
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., and Rowe, C. C. (2015). Tau imaging: early progress and future directions. Lancet Neurol. 14, 114–124. doi: 10.1016/S1474-4422(14)70252-2
Villemagne, V. L., Furumoto, S., Fodero-Tavoletti, M. T., Harada, R., Mulligan, R. S., Kudo, Y., et al. (2012). The challenges of tau imaging. Future Neurol. 7, 409–421. doi: 10.2217/fnl.12.34
Villemagne, V. L., Furumoto, S., Fodero-Tavoletti, M. T., Mulligan, R. S., Hodges, J., Harada, R., et al. (2014). In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 41, 816–826. doi: 10.1007/s00259-013-2681-7
Walji, A. M., Hostetler, E. D., Selnick, H., Zeng, Z., Miller, P., Bennacef, I., et al. (2016). Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J. Med. Chem. 59, 4778–4789. doi: 10.1021/acs.jmedchem.6b00166
Wong, D. F., Comley, R., Kuwabara, H., Rosenberg, P. B., Resnick, S. M., Ostrowitzki, S., et al. (2018). First in-human PET study of 3 novel tau radiopharmaceuticals: [(11)C]RO 6924963, [(11)C]RO 6931643, and [(18)F]RO6958948. J. Nucl. Med. [Epub ahead of print].
Xia, C., Makaretz, S. J., Caso, C., Mcginnis, S., Gomperts, S. N., Sepulcre, J., et al. (2017). Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 74, 427–436. doi: 10.1001/jamaneurol.2016.5755
Xia, C. F., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., et al. (2013). [(18)F]T 807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 9, 666–676. doi: 10.1016/j.jalz.2012.11.008
Yoshimi, T., Kawabata, S., Taira, S., Okuno, A., Mikawa, R., Murayama, S., et al. (2015). Affinity imaging mass spectrometry (AIMS): high-throughput screening for specific small molecule interactions with frozen tissue sections. Analyst 140, 7202–7208. doi: 10.1039/c5an01381j
Keywords: proteinopathies, protein aggregates, β-sheet ligands, PET, tau
Citation: Harada R, Okamura N, Furumoto S and Yanai K (2018) Imaging Protein Misfolding in the Brain Using β-Sheet Ligands. Front. Neurosci. 12:585. doi: 10.3389/fnins.2018.00585
Received: 28 November 2017; Accepted: 06 August 2018;
Published: 21 August 2018.
Edited by:
Gen Sobue, Nagoya University, JapanReviewed by:
Michael D. Devous, Avid Radiopharmaceuticals, Inc., United StatesJason Eriksen, University of Houston, United States
Copyright © 2018 Harada, Okamura, Furumoto and Yanai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kazuhiko Yanai, yanai@med.tohoku.ac.jp